LTS bids farewell to Prof. Dr. Christof Hettich
It is with great sadness and deep respect that we bid farewell to Prof. Dr. Christof Hettich, who was closely associated with LTS Lohmann Therapie-Systeme AG for many years.
LTS Awarded Ecovadis Gold for Sustainability Performance
LTS has been awarded the Gold Medal in the Ecovadis Sustainability Rating, placing the company among the top 5% of all companies assessed worldwide.
LTS Supports Flood Recovery Efforts in the Ahr Valley
Recently, members of our team visited the Ahr Valley to gain insights into the ongoing recovery efforts following the devastating floods
LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities
LTS LOHMANN Therapie-Systeme AG today announced the successful closing of its acquisition of Renaissance Lakewood, LLC.
Federal President Steinmeier visits LTS Lohmann Therapie-Systeme AG in Andernach
Federal President Steinmeier visits LTS Lohmann Therapie-Systeme AG in Andernach
LTS expands its CDMO capabilities with the acquisition of Renaissance Lakewood
LTS announces the acquisition of Renaissance Lakewood, LLC a US-based contract development and manufacturing organization specializing in nasal sprays and sterile dosage forms.
LTS and Nualtis sign Business Development Term Sheet to Advance Montelukast Oral Thin Film for Parkinson’s and Alzheimer’s Disease
This collaboration between Nualtis and LTS is aimed at rapidly advancing Montelukast Oral Thin Film for the treatment of Parkinson’s and Alzheimer’s.
Microarray Patch Technology – A Promising Step Forward in Multiple Sclerosis Therapy
We have successfully demonstrated that our MAP technology can deliver beta interferon as effectively as traditional injections, but with added benefits for patients.
Our science-based targets under the SBTi
In February 2023, we committed to setting science-based targets under the SBTi – the Science Based Targets initiative. SBTi is the global gold standard when it comes to climate targets.
With innovations into the future
Always looking for new, advantageous delivery forms of administration, LTS has been intensively researching microneedle systems for the administration of active ingredients to patients.